[{"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-001", "question": "A 58-year-old man undergoes pancreaticoduodenectomy for a 2.5 cm pancreatic head adenocarcinoma. On postoperative day 3, his closed-suction drain has serous output of 25 mL/24 hours. Drain fluid amylase is 1,200 U/L (serum amylase 150 U/L). He is afebrile, hemodynamically stable, with soft abdomen and no leukocytosis. What is the most appropriate next step in management?", "options": ["Remove the drain", "Keep the drain and start octreotide", "Obtain contrast-enhanced CT of abdomen", "Keep the drain and discharge to home", "Return to operating room for exploration"], "answer": "A", "answer_index": 0, "explanation": "The 2016 ISGPS update defines a 'biochemical leak' as drain fluid amylase >3x serum on POD 1-3 with output <30 mL/day and no clinical sequelae, which can be managed by drain removal. Grade B fistula requires output >30 mL/day or clinical impact. The high amylase alone does not mandate retention if output remains low and the patient is clinically well.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Postoperative day 3 after pancreaticoduodenectomy; drain output is low volume (25 mL/24 h), serous; drain amylase 1,200 U/L vs serum 150 U/L (>3× serum); patient is clinically well—afebrile, hemodynamically stable, soft abdomen, no leukocytosis. These findings match an ISGPS “biochemical leak” (formerly Grade A), not a clinically significant pancreatic fistula. Per 2016 ISGPS update, this entity has no clinical impact and is managed by drain removal when output is low and patient is stable.\\nChoice A (remove the drain) aligns directly with this definition and recommended management. B (keep drain and start octreotide) is unnecessary because there is no clinically relevant fistula; somatostatin analogs are not routinely indicated. C (CT) is unwarranted without sepsis, pain, or hemodynamic instability. D (keep drain and discharge) contradicts guidance; retaining a drain for a mere biochemical leak is not indicated. E (reoperation) is clearly excessive.\\nNo logical inconsistencies or competing defensible options are present.\\nMinimal fix: Clarify that the drain was placed at the time of pancreaticojejunostomy to reinforce the pancreatic leak context, though this is already strongly implied and not required for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Postoperative day 3 after pancreaticoduodenectomy; drain output is low volume (25 mL/24 h), serous; drain amylase 1,200 U/L vs serum 150 U/L (>3× serum); patient is clinically well—afebrile, hemodynamically stable, soft abdomen, no leukocytosis. These findings match an ISGPS “biochemical leak” (formerly Grade A), not a clinically significant pancreatic fistula. Per 2016 ISGPS update, this entity has no clinical impact and is managed by drain removal when output is low and patient is stable.\nChoice A (remove the drain) aligns directly with this definition and recommended management. B (keep drain and start octreotide) is unnecessary because there is no clinically relevant fistula; somatostatin analogs are not routinely indicated. C (CT) is unwarranted without sepsis, pain, or hemodynamic instability. D (keep drain and discharge) contradicts guidance; retaining a drain for a mere biochemical leak is not indicated. E (reoperation) is clearly excessive.\nNo logical inconsistencies or competing defensible options are present.\nMinimal fix: Clarify that the drain was placed at the time of pancreaticojejunostomy to reinforce the pancreatic leak context, though this is already strongly implied and not required for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-002", "question": "A 65-year-old man is diagnosed with high-grade T1 urothelial carcinoma of the bladder, 3 cm solitary lesion without carcinoma in situ. His EORTC risk score is 8. He is scheduled to begin intravesical BCG immunotherapy. What is the optimal evidence-based regimen?", "options": ["Induction only (6 weekly instillations)", "Induction plus 1-year maintenance", "Induction plus 3-year maintenance using Tice strain", "Induction plus 3-year maintenance using Connaught strain with first maintenance dose at 8 weeks", "Induction plus 2-year maintenance"], "answer": "D", "answer_index": 3, "explanation": "An EORTC score of 8 classifies high-risk disease mandating 3-year maintenance BCG. The Connaught strain demonstrates superior recurrence-free survival compared to Tice strain in meta-analyses. Maintenance must commence 8 weeks after induction completion. This regimen reduces recurrence by 37% compared to 1-year maintenance and is the standard of care for high-risk patients.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Miskeyed / not defensible as written\\nKey stem clues: 65-year-old man, high-grade T1 non–muscle-invasive urothelial carcinoma, solitary 3‑cm lesion, EORTC score 8 (high risk), planned intravesical BCG. For high-risk NMIBC, standard evidence-based regimens (e.g., SWOG 8507) support induction BCG plus up to 3 years of maintenance; choice of strain (Connaught vs Tice) and exact superiority is controversial and not guideline‑mandated. No major guideline specifies that maintenance must start exactly 8 weeks after induction or that Connaught is clearly superior or standard of care.\\nMain logical issues: The question asks for an “optimal evidence-based regimen” but includes highly specific, debatable claims about Connaught strain superiority and an 8‑week maintenance start that are not broadly accepted standards. None of the options cleanly matches guideline-based teaching (induction plus up to 3 years maintenance) without embedding questionable details, so no option is unequivocally defensible.\\nMain medical accuracy issues: Overstated Connaught superiority; rigid 8‑week timing; labeling this as standard of care.\\nMinimal fix: Replace D with “Induction plus 3-year maintenance BCG as per SWOG schedule” and key that option; remove strain- and exact‑week specifications from stem and rationale.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Miskeyed / not defensible as written\nKey stem clues: 65-year-old man, high-grade T1 non–muscle-invasive urothelial carcinoma, solitary 3‑cm lesion, EORTC score 8 (high risk), planned intravesical BCG. For high-risk NMIBC, standard evidence-based regimens (e.g., SWOG 8507) support induction BCG plus up to 3 years of maintenance; choice of strain (Connaught vs Tice) and exact superiority is controversial and not guideline‑mandated. No major guideline specifies that maintenance must start exactly 8 weeks after induction or that Connaught is clearly superior or standard of care.\nMain logical issues: The question asks for an “optimal evidence-based regimen” but includes highly specific, debatable claims about Connaught strain superiority and an 8‑week maintenance start that are not broadly accepted standards. None of the options cleanly matches guideline-based teaching (induction plus up to 3 years maintenance) without embedding questionable details, so no option is unequivocally defensible.\nMain medical accuracy issues: Overstated Connaught superiority; rigid 8‑week timing; labeling this as standard of care.\nMinimal fix: Replace D with “Induction plus 3-year maintenance BCG as per SWOG schedule” and key that option; remove strain- and exact‑week specifications from stem and rationale.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-003", "question": "A 72-year-old woman with metastatic melanoma on combination ipilimumab/nivolumab develops six watery stools daily. Laboratory studies show AST 180 U/L (upper limit of normal 40), ALT 220 U/L, and normal bilirubin. Colonoscopy reveals ulcerative colitis-like changes. What is the next step in management?", "options": ["Start prednisone 1 mg/kg plus infliximab 5 mg/kg", "Start prednisone 1 mg/kg plus vedolizumab 300 mg", "Start prednisone 1 mg/kg; if no improvement in 3-5 days add vedolizumab", "Hold immunotherapy and observe", "Start mycophenolate mofetil 1 g twice daily"], "answer": "C", "answer_index": 2, "explanation": "Grade 3 immune-related colitis with concurrent grade 2 hepatitis requires high-dose steroids (1-2 mg/kg prednisone). Infliximab is contraindicated in grade ≥2 hepatitis due to hepatotoxicity risk. Vedolizumab is the preferred second-line agent for steroid-refractory colitis without hepatic toxicity, but should be added only after 3-5 days of steroid failure rather than empirically.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 72-year-old on ipilimumab/nivolumab; six watery stools daily with ulcerative colitis–like changes on colonoscopy (immune-related colitis, at least grade 3 given frequency and endoscopic findings); AST/ALT ~4–5× ULN with normal bilirubin (grade 2 immune-related hepatitis); on combination CTLA-4/PD-1 therapy.\\nThe appropriate management is to treat this as grade ≥3 immune-related colitis plus grade 2 hepatitis: initiate high-dose systemic corticosteroids (prednisone 1–2 mg/kg or IV equivalent), monitor response, and reserve a non-hepatotoxic biologic (vedolizumab) if colitis is steroid-refractory after 3–5 days. Thus option C—start prednisone 1 mg/kg and add vedolizumab only if no improvement in 3–5 days—is consistent with current irAE guidelines.\\nOption A incorrectly uses infliximab despite concurrent grade 2 hepatitis (contraindicated). Option B adds vedolizumab up front instead of as second-line. Option D (observation only) under-treats grade 3 colitis/hepatitis. Option E (mycophenolate) is generally reserved for steroid-refractory hepatitis, not first-line for colitis.\\nMinimal fix: Explicitly state CTCAE colitis/hepatitis grades in the stem to remove any ambiguity about severity classification and treatment thresholds.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 72-year-old on ipilimumab/nivolumab; six watery stools daily with ulcerative colitis–like changes on colonoscopy (immune-related colitis, at least grade 3 given frequency and endoscopic findings); AST/ALT ~4–5× ULN with normal bilirubin (grade 2 immune-related hepatitis); on combination CTLA-4/PD-1 therapy.\nThe appropriate management is to treat this as grade ≥3 immune-related colitis plus grade 2 hepatitis: initiate high-dose systemic corticosteroids (prednisone 1–2 mg/kg or IV equivalent), monitor response, and reserve a non-hepatotoxic biologic (vedolizumab) if colitis is steroid-refractory after 3–5 days. Thus option C—start prednisone 1 mg/kg and add vedolizumab only if no improvement in 3–5 days—is consistent with current irAE guidelines.\nOption A incorrectly uses infliximab despite concurrent grade 2 hepatitis (contraindicated). Option B adds vedolizumab up front instead of as second-line. Option D (observation only) under-treats grade 3 colitis/hepatitis. Option E (mycophenolate) is generally reserved for steroid-refractory hepatitis, not first-line for colitis.\nMinimal fix: Explicitly state CTCAE colitis/hepatitis grades in the stem to remove any ambiguity about severity classification and treatment thresholds.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-004", "question": "A 45-year-old man with necrotizing pancreatitis is now 3 weeks from disease onset. Contrast-enhanced CT demonstrates a 9-cm walled-off necrosis in the lesser sac with a mature, well-defined wall. ERCP confirms disconnected pancreatic duct syndrome. He is febrile to 38.5°C with WBC 15,000 cells/µL. What is the definitive management?", "options": ["Immediate percutaneous catheter drainage", "Endoscopic ultrasound-guided cystgastrostomy now", "Surgical cystgastrostomy with necrosectomy now", "Delay intervention until 4 weeks then proceed endoscopically", "Continue antibiotics and observe"], "answer": "C", "answer_index": 2, "explanation": "The 2020 revised Atlanta guidelines permit intervention when WON demonstrates a mature wall, eliminating the mandatory 4-week wait. Disconnected pancreatic duct syndrome is a surgical indication because endoscopic drainage alone is associated with 40% recurrence. Surgical cystgastrostomy with necrosectomy definitively addresses both the necrosis and ductal disruption, reducing recurrence to <10%.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Necrotizing pancreatitis; 3 weeks from onset; contrast CT shows 9‑cm walled‑off necrosis (WON) with a mature, well‑defined wall in lesser sac; ERCP confirms disconnected pancreatic duct syndrome (DPDS); patient is febrile and leukocytic (infected WON); question asks for “definitive management.” Current data/guidelines support that: (1) intervention for infected/walled‑off necrosis can proceed as soon as there is a mature wall, not strictly ≥4 weeks; (2) in confirmed DPDS, simple endoscopic drainage carries high recurrence and surgical internal drainage (e.g., cystgastrostomy with necrosectomy) is often considered definitive therapy. Thus option C fits both infected WON requiring intervention and the need for definitive treatment of DPDS.\\nOther options: A and B are temporizing or non‑definitive, especially with DPDS and high recurrence; D incorrectly enforces a rigid 4‑week rule and still would use endoscopy alone; E is inappropriate in infected WON with sepsis signs and large 9‑cm collection. Medical accuracy is generally solid and contemporary, though some centers manage DPDS endoscopically; for a single‑best exam item, surgery as definitive is defensible. Minimal fix: explicitly add “septic from infected WON requiring definitive therapy for DPDS” to clarify urgency and intent.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Necrotizing pancreatitis; 3 weeks from onset; contrast CT shows 9‑cm walled‑off necrosis (WON) with a mature, well‑defined wall in lesser sac; ERCP confirms disconnected pancreatic duct syndrome (DPDS); patient is febrile and leukocytic (infected WON); question asks for “definitive management.” Current data/guidelines support that: (1) intervention for infected/walled‑off necrosis can proceed as soon as there is a mature wall, not strictly ≥4 weeks; (2) in confirmed DPDS, simple endoscopic drainage carries high recurrence and surgical internal drainage (e.g., cystgastrostomy with necrosectomy) is often considered definitive therapy. Thus option C fits both infected WON requiring intervention and the need for definitive treatment of DPDS.\nOther options: A and B are temporizing or non‑definitive, especially with DPDS and high recurrence; D incorrectly enforces a rigid 4‑week rule and still would use endoscopy alone; E is inappropriate in infected WON with sepsis signs and large 9‑cm collection. Medical accuracy is generally solid and contemporary, though some centers manage DPDS endoscopically; for a single‑best exam item, surgery as definitive is defensible. Minimal fix: explicitly add “septic from infected WON requiring definitive therapy for DPDS” to clarify urgency and intent.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-005", "question": "A 58-year-old kidney transplant recipient (deceased donor, 8 months post-transplant) presents with rising creatinine from 1.2 to 2.1 mg/dL. Plasma BK virus PCR is 18,000 copies/mL. Allograft biopsy shows Banff class B BK virus nephropathy. Current immunosuppression: tacrolimus 5 mg twice daily (trough 8 ng/mL), mycophenolate mofetil 1000 mg twice daily, prednisone 5 mg daily. What is the first immunosuppression modification?", "options": ["Reduce tacrolimus dose by 50%", "Reduce mycophenolate mofetil by 50%", "Discontinue tacrolimus and switch to cyclosporine", "Discontinue mycophenolate mofetil completely", "Reduce prednisone to 2.5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "For BK viremia >10,000 copies/mL with Banff class B nephropathy, first-line therapy is mycophenolate dose reduction by 50% or complete discontinuation. Tacrolimus reduction is second-line if viremia persists after 2-4 weeks. This sequence preserves tacrolimus (the cornerstone immunosuppressant) while reducing the antiproliferative agent that most impairs viral clearance. Steroids should not be reduced initially.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Kidney transplant recipient 8 months post-transplant; rising creatinine; high-level BK viremia (18,000 copies/mL); biopsy-proven Banff class B BK virus nephropathy; on triple therapy with tacrolimus at a reasonable trough, mycophenolate 1000 mg BID, and low-dose prednisone 5 mg. In current practice and guideline-based algorithms, initial management of biopsy-proven BK nephropathy is stepwise reduction of overall immunosuppression, usually starting with the antimetabolite (mycophenolate) by 25–50%, with consideration of discontinuation, then adjusting the calcineurin inhibitor if viremia does not improve.\\nChoice B (reduce mycophenolate by 50%) is therefore the most appropriate first modification. Choice A (reduce tacrolimus 50%) is typically a second-step change after antimetabolite reduction fails. C (switch to cyclosporine) and D (immediate discontinuation of MMF) are excessive first-line steps; E (reducing prednisone from 5 to 2.5 mg) is not a recommended primary strategy and has minimal impact. No major internal contradictions or underspecification are present.\\nMinimal fix: Add a phrase such as “According to standard stepwise BK management protocols” to reinforce the sequence rationale, though not strictly necessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Kidney transplant recipient 8 months post-transplant; rising creatinine; high-level BK viremia (18,000 copies/mL); biopsy-proven Banff class B BK virus nephropathy; on triple therapy with tacrolimus at a reasonable trough, mycophenolate 1000 mg BID, and low-dose prednisone 5 mg. In current practice and guideline-based algorithms, initial management of biopsy-proven BK nephropathy is stepwise reduction of overall immunosuppression, usually starting with the antimetabolite (mycophenolate) by 25–50%, with consideration of discontinuation, then adjusting the calcineurin inhibitor if viremia does not improve.\nChoice B (reduce mycophenolate by 50%) is therefore the most appropriate first modification. Choice A (reduce tacrolimus 50%) is typically a second-step change after antimetabolite reduction fails. C (switch to cyclosporine) and D (immediate discontinuation of MMF) are excessive first-line steps; E (reducing prednisone from 5 to 2.5 mg) is not a recommended primary strategy and has minimal impact. No major internal contradictions or underspecification are present.\nMinimal fix: Add a phrase such as “According to standard stepwise BK management protocols” to reinforce the sequence rationale, though not strictly necessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T234023630Z_kimi-k2-thinking_seed133", "question_id": "20251225T234023630Z_kimi-k2-thinking_seed133-006", "question": "A 62-year-old man with metastatic melanoma receives axicabtagene ciloleucel. On day 7 post-infusion, he develops confusion, expressive aphasia, and asterixis. He has a low-grade fever (37.8°C) only. ICE score is 8/10. EEG demonstrates triphasic waves. Brain MRI is normal. What is the immediate management?", "options": ["Tocilizumab 8 mg/kg intravenously once", "Dexamethasone 10 mg intravenously every 6 hours", "Methylprednisolone 1 g intravenously daily", "Tocilizumab plus dexamethasone 10 mg every 6 hours", "Supportive care with scheduled haloperidol"], "answer": "B", "answer_index": 1, "explanation": "An ICE score of 8 indicates grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS), which requires dexamethasone 10 mg IV q6h. Tocilizumab is indicated for cytokine release syndrome (CRS), not ICANS, and is unnecessary for grade 1 CRS. High-dose methylprednisolone is reserved for grade ≥3 ICANS. The EEG findings are characteristic but do not escalate management beyond standard ICANS algorithms.", "generator_model": "kimi-k2-thinking", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Day 7 after axicabtagene (CD19 CAR T), new confusion and expressive aphasia with asterixis; ICE score 8/10; low-grade fever only; normal brain MRI; EEG with triphasic waves. These findings are classic for grade 2 ICANS without significant concurrent CRS. Standard grading defines ICE 7–9 with no depressed consciousness, seizures, or focal edema as grade 2 ICANS. Current ASTCT/CAR-T management algorithms recommend dexamethasone 10 mg IV every 6 hours for grade 2 ICANS, escalating to high-dose methylprednisolone for grade ≥3.\\nOption analysis: A (tocilizumab alone) targets CRS, not isolated ICANS. C (1 g methylpred) is excessive for grade 2; reserved for more severe neurotoxicity. D (tocilizumab plus dexamethasone) is for ICANS with significant CRS, not supported by only low-grade fever. E (supportive care and haloperidol) under-treats grade 2 ICANS and introduces potentially deliriogenic medication.\\nMain issues: None substantial; triphasic waves are correctly treated as characteristic but not management changing. Medical content is contemporary and guideline-consistent.\\nMinimal fix: Explicitly state absence of hypotension/hypoxia to further rule out significant CRS and reinforce why tocilizumab is not indicated.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Day 7 after axicabtagene (CD19 CAR T), new confusion and expressive aphasia with asterixis; ICE score 8/10; low-grade fever only; normal brain MRI; EEG with triphasic waves. These findings are classic for grade 2 ICANS without significant concurrent CRS. Standard grading defines ICE 7–9 with no depressed consciousness, seizures, or focal edema as grade 2 ICANS. Current ASTCT/CAR-T management algorithms recommend dexamethasone 10 mg IV every 6 hours for grade 2 ICANS, escalating to high-dose methylprednisolone for grade ≥3.\nOption analysis: A (tocilizumab alone) targets CRS, not isolated ICANS. C (1 g methylpred) is excessive for grade 2; reserved for more severe neurotoxicity. D (tocilizumab plus dexamethasone) is for ICANS with significant CRS, not supported by only low-grade fever. E (supportive care and haloperidol) under-treats grade 2 ICANS and introduces potentially deliriogenic medication.\nMain issues: None substantial; triphasic waves are correctly treated as characteristic but not management changing. Medical content is contemporary and guideline-consistent.\nMinimal fix: Explicitly state absence of hypotension/hypoxia to further rule out significant CRS and reinforce why tocilizumab is not indicated.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]